TC BioPharm (Holdings) PLC (TCBP)
1.53
-0.04
(-2.55%)
USD |
NASDAQ |
Apr 26, 16:00
1.54
+0.01
(+0.65%)
After-Hours: 20:00
TC BioPharm Cash from Financing (TTM): 10.62M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.62M |
| June 30, 2023 | 11.45M |
| Date | Value |
|---|---|
| December 31, 2022 | 23.00M |
| June 30, 2022 | 18.72M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
10.62M
Minimum
Dec 2023
23.00M
Maximum
Dec 2022
15.95M
Average
15.09M
Median
Cash from Financing (TTM) Benchmarks
| Adaptimmune Therapeutics PLC | 0.88M |
| Biodexa Pharmaceuticals Plc | 12.76M |
| NuCana PLC | -0.0659M |
| Autolus Therapeutics PLC | -0.883M |
| Mereo BioPharma Group PLC | 7.973M |